ENVERIC BIOSCIENCES, INC. Accounts Receivable
ENVERIC BIOSCIENCES, INC. (ENVB) had Accounts Receivable of $7.56 million as of 2020-09-30, per its 10-Q filed 2020-11-16.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:AccountsReceivableNetCurrent · last filed 2020-11-16
- 2020-09-30: Accounts Receivable, after Allowance for Credit Loss, Current $7.56M.
- 2020-06-30: Accounts Receivable, after Allowance for Credit Loss, Current $7.29M.
- 2020-03-31: Accounts Receivable, after Allowance for Credit Loss, Current $8.10M.
- 2019-12-31: Accounts Receivable, after Allowance for Credit Loss, Current $6.38M.
| Period end | Accounts Receivable, after Allowance for Credit Loss, Current |
|---|---|
| 2020-09-30 | $7.56M 10-Q · filed 2020-11-16 |
| 2020-06-30 | $7.29M 10-Q · filed 2020-08-14 |
| 2020-03-31 | $8.10M 10-Q · filed 2020-05-15 |
| 2019-12-31 | $6.38M 10-Q · filed 2020-11-16 |
| 2019-09-30 | $7.61M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $8.54M 10-Q · filed 2019-08-14 |
| 2019-03-31 | $8.90M 10-Q · filed 2019-05-14 |
| 2018-12-31 | $7.87M 10-K/A · filed 2020-08-12 |
| 2018-09-30 | $7.83M 10-Q · filed 2018-11-14 |
| 2018-06-30 | $7.94M 10-Q · filed 2018-08-14 |
| 2018-03-31 | $8.46M 10-Q · filed 2018-05-15 |
| 2017-12-31 | $8.84M 10-K · filed 2019-03-26 |
| 2017-09-30 | $9.17M 10-Q · filed 2017-11-13 |
| 2017-06-30 | $8.72M 10-Q · filed 2017-08-14 |
| 2017-03-31 | $9.59M 10-Q/A · filed 2017-05-15 |
| 2016-12-31 | $8.06M 10-K · filed 2018-04-02 |
| 2016-09-30 | $7.72M 10-Q · filed 2016-11-14 |
| 2016-06-30 | $4.13M 10-Q · filed 2016-08-12 |
| 2016-03-31 | $4.93M 10-Q · filed 2016-05-16 |
| 2015-12-31 | $4.87M 10-K/A · filed 2017-04-04 |
| 2015-09-30 | $8.96M 10-Q · filed 2015-11-23 |
| 2015-06-30 | $4.68M 10-Q · filed 2015-08-18 |
| 2015-03-31 | $2.98M 10-KT · filed 2016-03-15 |
| 2014-03-31 | $2.94M 10-KT · filed 2016-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |